BiomX (PHGE) Long-Term Investments (2018 - 2023)

BiomX (PHGE) posted Long-Term Investments of $23.9 million for Q1 2023, down 14.11% sequentially from $27.8 million in Q4 2022.

BiomX (PHGE) Long-Term Investments (2018 - 2023) Analysis & Trends

BiomX has reported Long-Term Investments for 4 years, with the latest figure at $23.9 million in Q1 2023.

Quarterly Long-Term Investments changed N/A year-over-year to $23.9 million in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $23.9 million (changed N/A YoY) and the FY2022 annual result came in at $27.8 million, changed N/A from the prior year.
Long-Term Investments retreated to $23.9 million in Q1 2023 per PHGE's latest filing, from $27.8 million in the prior quarter.
Over five years, Long-Term Investments peaked at $71.1 million in Q3 2019 and troughed at $23.9 million in Q1 2023.
A 3-year average of $52.8 million and a median of $70.5 million in 2019 frame the typical range for Long-Term Investments.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Investments (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	5.79 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	9.83 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	1.77 Bn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	22.17 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	372.10 Mn
10	BiomX	351,774.34	-816,225.66	-	-

Download Data